IDH2 and neoplasm: The tumor-suppressive activity of IDH mutation is indicated by the finding that D-2-hydroxyglutarate—the distinct metabolite produced from IDH mutations—exerts an anti-tumor activity by attenuating aerobic glycolysis in leukemia cells [22].